The University of Southampton
University of Southampton Institutional Repository

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia
The combination of bortezomib and rituximab was evaluated in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL) and Waldenström macroglobulinaemia (WM), in a Phase I and later, a randomized Phase II study. In the randomized study, 42 patients with recurrent/refractory disease received either: bortezomib 1·3 mg/m2 on days 1, 4, 8 and 11 of a 3-week cycle with rituximab 375 mg/m2 on day 1 (21 patients) or: bortezomib 1·6 mg/m2 and rituximab on days 1, 8, 15 and 22 of a 5-week cycle (with rituximab being given only in cycles 1 and 4).Twenty-eight patients were withdrawn (toxicity 16, progression 7, and ‘patient choice’ 5). The main toxicities were neurological, gastro-intestinal and haematological. The overall response rate was 28/42(67%) and by histology: MCL 11/19, FL 8/15, and WM 9/10. Ten of 28 responding patients remained progression-free at 1–3·5 years. Toxicity and efficacy were equivalent between the two groups. The combination has significant toxicity but is effective, particularly in patients with WM.
bortezomib, rituximab, b-cell malignancies
0007-1048
346-353
Agathocleous, Agathoclis
79edc9b4-d482-4ff8-863e-249bd49ed00b
Rohatiner, Ama
a8294ba6-84f3-4777-a499-c4e71ddf4a98
Rule, Simon
cc835ff1-f9a5-47a4-b815-76e516e157e7
Hunter, Hannah
b2e9eda9-2ea6-4fcb-b7e3-5f592032e688
Kerr, Jonathan Paul
04e0fefe-af4b-4654-a3e9-d1e6fdd4e6c8
Neeson, Susan M.
96e87350-30e2-4316-b9a9-d1883b9f7d49
Mathews, Janet
fc5595c2-06e2-424f-96bc-1b35fd2df701
Strauss, Sandra
878a7e05-9cc8-471e-9fc2-d7916b3944ae
Montoto, Silvia
890fe3f0-1910-49b4-97d4-993e2701052f
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Radford, John
10af63a2-6f8d-4305-b150-0e76925a64aa
Lister, Andrew
5c49b371-d2b7-4e19-912d-b494584c554a
Agathocleous, Agathoclis
79edc9b4-d482-4ff8-863e-249bd49ed00b
Rohatiner, Ama
a8294ba6-84f3-4777-a499-c4e71ddf4a98
Rule, Simon
cc835ff1-f9a5-47a4-b815-76e516e157e7
Hunter, Hannah
b2e9eda9-2ea6-4fcb-b7e3-5f592032e688
Kerr, Jonathan Paul
04e0fefe-af4b-4654-a3e9-d1e6fdd4e6c8
Neeson, Susan M.
96e87350-30e2-4316-b9a9-d1883b9f7d49
Mathews, Janet
fc5595c2-06e2-424f-96bc-1b35fd2df701
Strauss, Sandra
878a7e05-9cc8-471e-9fc2-d7916b3944ae
Montoto, Silvia
890fe3f0-1910-49b4-97d4-993e2701052f
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Radford, John
10af63a2-6f8d-4305-b150-0e76925a64aa
Lister, Andrew
5c49b371-d2b7-4e19-912d-b494584c554a

Agathocleous, Agathoclis, Rohatiner, Ama, Rule, Simon, Hunter, Hannah, Kerr, Jonathan Paul, Neeson, Susan M., Mathews, Janet, Strauss, Sandra, Montoto, Silvia, Johnson, Peter, Radford, John and Lister, Andrew (2010) Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. British Journal of Haematology, 151 (4), 346-353. (doi:10.1111/j.1365-2141.2010.08340.x). (PMID:20880120)

Record type: Article

Abstract

The combination of bortezomib and rituximab was evaluated in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL) and Waldenström macroglobulinaemia (WM), in a Phase I and later, a randomized Phase II study. In the randomized study, 42 patients with recurrent/refractory disease received either: bortezomib 1·3 mg/m2 on days 1, 4, 8 and 11 of a 3-week cycle with rituximab 375 mg/m2 on day 1 (21 patients) or: bortezomib 1·6 mg/m2 and rituximab on days 1, 8, 15 and 22 of a 5-week cycle (with rituximab being given only in cycles 1 and 4).Twenty-eight patients were withdrawn (toxicity 16, progression 7, and ‘patient choice’ 5). The main toxicities were neurological, gastro-intestinal and haematological. The overall response rate was 28/42(67%) and by histology: MCL 11/19, FL 8/15, and WM 9/10. Ten of 28 responding patients remained progression-free at 1–3·5 years. Toxicity and efficacy were equivalent between the two groups. The combination has significant toxicity but is effective, particularly in patients with WM.

Full text not available from this repository.

More information

Published date: November 2010
Keywords: bortezomib, rituximab, b-cell malignancies
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 180085
URI: https://eprints.soton.ac.uk/id/eprint/180085
ISSN: 0007-1048
PURE UUID: 7679d034-0790-440f-b1ad-046342d38b58
ORCID for Peter Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 06 Apr 2011 10:39
Last modified: 20 Jul 2019 01:12

Export record

Altmetrics

Contributors

Author: Agathoclis Agathocleous
Author: Ama Rohatiner
Author: Simon Rule
Author: Hannah Hunter
Author: Jonathan Paul Kerr
Author: Susan M. Neeson
Author: Janet Mathews
Author: Sandra Strauss
Author: Silvia Montoto
Author: Peter Johnson ORCID iD
Author: John Radford
Author: Andrew Lister

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×